

Development of a First-in-Class IVIG Glyco-Based Ophthalmic Eye Drop Candidate for Uveitis Treatment

INUS IMMUNE Co., Ltd.

INUS IMMUNE

IMMUNOLOGY	Candidate
Product Type	rProtein
Indication	Non-infectious Uveitis, Ocular Surface Inflammatory Diseases
Target	Ocular Innate immune regulatory receptor pathway
MoA(Mechanism of Action)	First-in-Class immunomodulatory ophthalmic approach designed to restore ocular immune homeostasis through modulation of innate immune pathways and anti-inflammatory immune regulation
Competitiveness	• Novel mechanism based on restoration of immune homeostasis compared with conventional steroids and immunosuppressants • Potential to reduce steroid-associated adverse effects and relapse risk during long-term treatment • First-in-Class immunomodulatory therapeutic approach for inflammatory ophthalmic diseases • Differentiated biologics-based ophthalmic platform technology compared with conventional anti-inflammatory eye drops • Potential to utilize established safety references associated with IVIG-derived materials • Expandable platform potential for human ophthalmic and other inflammatory diseases
Development Stage	Candidate
Route of Administration	Ophthalmic Topical Eye Drops

Any unauthorized distribution or reproduction of this material is strictly prohibited.